Lipella Pharmaceuticals Inc. (LIPO) Stock Price & Analysis

Lipella Pharmaceuticals Inc. (LIPO) fell 20.00% to USD 0.08 as of June 10, 2026 at 06:58 UTC, according to Nexqual real-time market data.

LIPO last closed at USD 0.1; the session ranged USD 0.08–0.09 on volume of 18,946 shares. Market capitalization is $369,666, with a 52-week range of USD 0.02–2.96 (PNK). Source: Nexqual, June 10, 2026 at 06:58 UTC.

Key Statistics (as of June 10, 2026 at 06:58 UTC)

Technical Analysis (LIPO)

Nexqual's technical model rates LIPO "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 06:58 UTC.

Analyst Ratings (LIPO)

Wall Street analysts rate LIPO "None", per Nexqual as of June 10, 2026 at 06:58 UTC.

Earnings (LIPO)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 06:58 UTC.

Financials & Fundamentals (LIPO)

Source: Nexqual, June 10, 2026 at 06:58 UTC.

Financial Health Score (LIPO)

Nexqual rates Lipella Pharmaceuticals Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:58 UTC.

Ownership (LIPO)

Source: Nexqual, June 10, 2026 at 06:58 UTC.

Leadership (LIPO)

Lipella Pharmaceuticals Inc. is led by Jonathan Kaufman (age 59), Co-Founder, Chairman, CEO, President, Secretary & Treasurer, per Nexqual as of June 10, 2026 at 06:58 UTC.

From Lipella Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2025-03-28)

Key Strengths & Strategy (as disclosed to the SEC)

• Intravesical Administration," as well as in US patent publication number 2024/0115503 titled "Intravesical Delivery of Hydrophilic Therapeutic Agents Using Liposomes." We have a corresponding patent application pending in the U.S. (U.S.S.N 18/011,635).   Our Metastable Liposome Drug Delivery Platform   We have developed a proprietary technology, referred to as our Platform, which is optimized for local hydrophobic drug delivery to body cavities having endothelial surfaces.
• We received "orphan drug" designation from the FDA for the use of tacrolimus (including LP-10) for the treatment of HC.    We believe that our approach of using metastable liposomal tacrolimus as a treatment for HC, which has not yet been approved by the FDA, is novel.
• We are focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications.   We believe that our strategy combines many of the cost efficiencies and risk abatements derived from using existing generic drugs with potential patent protections for our proprietary formulations; this strategy allows us to expedite, protect, and monetize our product candidates.
• If successful, a pivotal phase 3 trial can be requested, and we believe the results of an LP-10 phase 3 trial could support the submission of an NDA for LP-10 to the FDA through the 505(b)(2) regulatory pathway and a Marketing Authorization Application to the EMA in Europe.

Partnerships

• Based on such price and demand estimates, we believe there is potential to receive up to $1.2 billion in annual gross revenue.   Our Lead Drug Candidates, LP-10, LP-310, and Our Product Pipeline   Five fundamental aspects of our LP-10 drug candidate make it an excellent fit for our strategy (see Figure 4 below).
• Approval: 1994."   Non-Clinical Study Results Involving Intravesical Tacrolimus   The following is a summary of non-clinical studies conducted with rats and dogs that were sponsored by the Company or conducted in collaboration with Company scientists.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:58 UTC. This page is informational and not investment advice.